Cubist Pharma Cvr (CBSTZ) 0.22 $CBSTZ
Antibiotics, Medicinal Plants, Superbugs And The Coming Antimicrobial Resistant Drugs Pandemic: Forecasts to 2019 and 128 Company Profiles
M2 - Fri May 09, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lk8nqf/antibiotics) has announced the addition of the "Antibiotics, Medicinal Plants, Superbugs And The Coming Antimicrobial Resistant Drugs Pandemic: Global Markets, Competitors And Opportunities - 2014-2019 Analysis And Forecasts" report to their offering. An Antibiotic is an agent that either kills or inhibits the growth of a microorganism. The world is now facing a grave situation: it is losing the battle against infectious diseases; bacteria are fighting back and are becoming resistant to modern medicine; in short, pharmaceutical drugs don't work. If resistance is allowed to increase, in a few decades people may start dying from the most commonplace of ailments that today can be treated easily. In fact, the ability of organisms to develop resistance to the effects of antimicrobial therapies developed to kill them is potentially the greatest challenge to healthcare in the 21st century. Antimicrobial resistance (AMR) is a form of drug resistance whereby some sub-populations of a microorganism, usually a bacterial species, are able to survive after exposure to one or more antibiotics. Pathogens resistant to multiple antibiotics are considered multidrug resistant (MDR) or, more colloquially, superbugs. Key Topics Covered: CONTENTS INTRODUCTION EXECUTIVE SUMMARY ANTIBIOTICS AND ANTIMICROBIAL RESISTANT DRUGS ANTIBIOTICS MARKET OVERVIEW PROSPECTS FOR PLANT-DERIVED ANTIBACTERIALS MEDICINAL PLANT MARKET COMPANY PROFILES Companies Mentioned: - A. Baur & Co (Pvt.) Ltd. - A. M. Todd Botanical Therapeutics, LLC - A.A. Sayia & Company, Inc. - Adam Group - Adams Extract & Spice, LLC, - Afriplex - Akbar Brothers Ltd. - Alchem International - Alvita Tea - Ambo Exports - Asian Tea & Exports Ltd. - Balaji Agro International - Bart Ingredients Company Ltd - Bigelow Tea Company - Bio Foods Pvt Ltd - Brassica Teas - C.F. Sauer Company - Cape Natural Tea Products - Ceylon Black Tea Company - Ceylon Spice Company - Chamong Tee Exports Pvt. Ltd. - Choice Organic Teas - Christopher Ranch - Coetzee & Coetzee (Pty) Ltd. - Cubist Pharmaceuticals, Inc. - EOAS International - Establecimiento Las Mar?as - Everest Spices - Everson Spice Company - First Spice Mixing Company For more information visit http://www.researchandmarkets.com/research/lk...ntibiotics
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
New Drug Applications, Quarterly Results, and University Partnerships - Analyst Notes on Celgene, HCA, Thermo Fisher Scientific, Cubist and Agilent
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), HCA Holdings Inc. (NYSE: HCA), Thermo Fisher Scientific Inc. (NYSE: TMO), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1941-100free.
Global Opioid-Induced Constipation (OIC) Clinical Trials Report 2014 - Analysis of Top 19 Companies/Organisations
M2 - Mon Apr 28, 5:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4gnshl/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014" report to their offering. Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014" provides data on the Opioid-Induced Constipation (OIC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid-Induced Constipation (OIC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid-Induced Constipation (OIC). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Salix Pharmaceuticals Ltd. - AstraZeneca PLC - Mundipharma International Limited - Shionogi & Co., Ltd. - Cubist Pharmaceuticals, Inc. - Theravance, Inc. - Pfizer Inc. - Novartis AG - Alkermes Plc - Alkermes Inc. (Inactive) - Friedrich-Schiller-Universitat Jena - The University of Vermont - St. John's Health System - VU University Medical Center - Shriners Hospitals for Children - Kuopio University Hospital - British Columbia Cancer Agency - UMC Utrecht Holding BV - Ullevaal University Hospital For more information visit http://www.researchandmarkets.com/research/4g...oidinduced
Global Opioid Induced Bowel Dysfunction Clinical Trials Review 2014 Featuring the Top 9 Companies/Institutes in the Field
M2 - Mon Apr 28, 5:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxs8hs/opioid_induced) has announced the addition of the "Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014" report to their offering. Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014" provides data on the Opioid Induced Bowel Dysfunction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid Induced Bowel Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid Induced Bowel Dysfunction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies & Institutes - GlaxoSmithKline plc - Cubist Pharmaceuticals, Inc. - Salix Pharmaceuticals Ltd. - Sucampo Pharmaceuticals, Inc. - Shionogi & Co., Ltd. - Helsinn Holding S.A. - Yokohama City University Hospital - Mech-Sense - Kuopio University Hospital For more information visit http://www.researchandmarkets.com/research/qx...id_induced
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
Global Opioid-Induced Constipation (OIC) Therapeutics Pipeline Review 2014 - Analysis of 11 Companes & 13 Drug Profiles
M2 - Wed Apr 23, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3fs6f/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Cubist Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Theravance, Inc. - Sucampo Pharmaceuticals, Inc. - AIKO Biotechnology, Inc. - Synergy Pharmaceuticals, Inc. - S.L.A. Pharma AG - Develco Pharma Schweiz AG Drug Profiles - naloxegol - lubiprostone - methylnaltrexone bromide - methylnaltrexone bromide - naldemedine - bevenopran - naloxone hydrochloride PR - methylnaltrexone bromide - TD-1211 - naloxone hydrochloride SR - SP-333 - naloxone hydrochloride - (6-beta-naltrexol oxycodone) For more information visit http://www.researchandmarkets.com/research/l3...oidinduced
Cubist Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Tue Apr 22, 3:00PM CDT
--Non-GAAP Adjusted Operating Income of $18.8 Million; GAAP Operating Income of $28.3 Million
Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of One Lot of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter
Business Wire - Fri Apr 18, 10:59AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling one lot of CUBICIN(R) (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles, found in a single vial from this lot, produced by a contract manufacturer.
Global Klebsiella Pneumoniae Infections Pipeline Review 2014 - Analysis of 12 Companies & 21 Drug Profiles
M2 - Thu Apr 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frwd77/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Dainippon Sumitomo Pharma Co., Ltd. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Pfizer Inc. - Soligenix, Inc. - FOB Synthesis, Inc. - Phico Therapeutics Ltd. - Trana Discovery, Inc. - Cantab Biopharmaceuticals Limited - Procarta Biosystems Ltd - Northern Antibiotics Oy - Arsanis Biosciences GmbH Drug Profiles - CB-618 - RX-04 - Drugs for Gram-Negative Nonsocomial Infections - CB-027 - SM-295291 - SM-369926 - SGX-942 - Small Moleule To Inhibit Lipopolysaccharide For Nosocomial Infections - Antimicrobial Compounds for Bacterial Infections - NAB-741 - NAB-7061 - Monoclonal Antibody For Klebsiella Pneumoniae Infections - IBN-1 - PMBN-fMLF - PMEN-fMLF - FSI-1686 - SASPject PT-3.X - RX-05 - Snare Antibacterial For Gram Negative Infections - Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - MVX-506 For more information visit http://www.researchandmarkets.com/research/frwd77/klebsiella
Cubist to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Business Wire - Tue Apr 15, 7:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its first quarter financial results, business activities, and financial outlook.
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol.
Zacks Industry Outlook Highlights: Eli Lilly, AstraZeneca, Shire, Salix and Cubist Pharmaceuticals
PR Newswire - Thu Mar 27, 8:30AM CDT
Today, Zacks Equity Research discusses the Pharma & Biotech, including Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report), Shire (Nasdaq:SHPG-Free Report), Salix (Nasdaq:SLXP-Free Report) and Cubist Pharmaceuticals (Nasdaq:CBST-Free Report).
Avanir Pharmaceuticals names Dr Mark Corrigan to board
M2 - Thu Mar 20, 5:02AM CDT
Biopharmaceutical company Avanir Pharmaceuticals (NasdaqGS:AVNR) revealed on Wednesday the addition of Dr Mark Corrigan to its board of directors.
Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI).
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
PR Newswire - Tue Feb 04, 7:00AM CST
Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bacteremia - Pipeline Review, H2 2013 Report
M2 - Mon Jan 27, 2:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/qv84kq/bacteremia) has announced the addition of the "Bacteremia - Pipeline Review, H2 2013" report to their offering. 'Bacteremia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Scope - A snapshot of the global therapeutic scenario for Bacteremia. - A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacteremia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bacteremia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bacteremia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Cubist Pharmaceuticals, Inc. Nabriva Therapeutics AG Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/qv84kq/bacteremia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Antibiotics, Medicinal Plants, Superbugs And The Coming Antimicrobial Resistant Drugs Pandemic: Forecasts to 2019 and 128 Company Profiles
M2 - Fri May 09, 5:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lk8nqf/antibiotics) has announced the addition of the "Antibiotics, Medicinal Plants, Superbugs And The Coming Antimicrobial Resistant Drugs Pandemic: Global Markets, Competitors And Opportunities - 2014-2019 Analysis And Forecasts" report to their offering. An Antibiotic is an agent that either kills or inhibits the growth of a microorganism. The world is now facing a grave situation: it is losing the battle against infectious diseases; bacteria are fighting back and are becoming resistant to modern medicine; in short, pharmaceutical drugs don't work. If resistance is allowed to increase, in a few decades people may start dying from the most commonplace of ailments that today can be treated easily. In fact, the ability of organisms to develop resistance to the effects of antimicrobial therapies developed to kill them is potentially the greatest challenge to healthcare in the 21st century. Antimicrobial resistance (AMR) is a form of drug resistance whereby some sub-populations of a microorganism, usually a bacterial species, are able to survive after exposure to one or more antibiotics. Pathogens resistant to multiple antibiotics are considered multidrug resistant (MDR) or, more colloquially, superbugs. Key Topics Covered: CONTENTS INTRODUCTION EXECUTIVE SUMMARY ANTIBIOTICS AND ANTIMICROBIAL RESISTANT DRUGS ANTIBIOTICS MARKET OVERVIEW PROSPECTS FOR PLANT-DERIVED ANTIBACTERIALS MEDICINAL PLANT MARKET COMPANY PROFILES Companies Mentioned: - A. Baur & Co (Pvt.) Ltd. - A. M. Todd Botanical Therapeutics, LLC - A.A. Sayia & Company, Inc. - Adam Group - Adams Extract & Spice, LLC, - Afriplex - Akbar Brothers Ltd. - Alchem International - Alvita Tea - Ambo Exports - Asian Tea & Exports Ltd. - Balaji Agro International - Bart Ingredients Company Ltd - Bigelow Tea Company - Bio Foods Pvt Ltd - Brassica Teas - C.F. Sauer Company - Cape Natural Tea Products - Ceylon Black Tea Company - Ceylon Spice Company - Chamong Tee Exports Pvt. Ltd. - Choice Organic Teas - Christopher Ranch - Coetzee & Coetzee (Pty) Ltd. - Cubist Pharmaceuticals, Inc. - EOAS International - Establecimiento Las Mar?as - Everest Spices - Everson Spice Company - First Spice Mixing Company For more information visit http://www.researchandmarkets.com/research/lk...ntibiotics
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014: 76 Companies and 141 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/d62n92/methicillinresist) has announced the addition of the "Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Companies Involved in Therapeutics Development - AIMM Therapeutics B.V. - Absynth Biologics Limited - Agilvax, Inc. - Alchemia Limited - AmpliPhi Biosciences Corporation - Aphios Corporation - Aridis Pharmaceuticals LLC - Basilea Pharmaceutica AG - Bharat Biotech International Limited - Biota Pharmaceuticals, Inc. - Cantab Biopharmaceuticals Limited - Cellceutix Corporation - Cempra, Inc. - ConjuGon, Inc. - ContraFect Corporation - CrystalGenomics, Inc. - Cubist Pharmaceuticals, Inc. - DesignMedix, Inc. - Destiny Pharma Ltd. - Dong-A Socio Holdings Co Ltd - Durata Therapeutics, Inc. - Eli Lilly and Company - Enanta Pharmaceuticals, Inc. - Ensoltek Co., Ltd. - Evolva SA - Excelimmune, Inc. - Galapagos NV - GangaGen Inc. - Genentech, Inc. - Helix BioMedix, Inc.. Drug Profiles - oritavancin disphosphate - ceftobiprole medocaril - vancomycin hydrochoride - oritavancin disphosphate - tedizolid phosphate - HT-61 - omadacycline tosylate - brilacidin - TD-1792 - AR-301 - XF-73 - CG-400549 - WCK-771 - MRX-I - levonadifloxacin - vancomycin - LTX-109 - P-128 - dalbavancin - ceftaroline fosamil - lotilibcin - BC-7013 - MRX-I - NDV-3 Vaccine - SASPject PT1.2 - KRPAM-1977X - KRPAM-1977Y - EDP-788 - SAL-200 - LCB-010371 For more information visit http://www.researchandmarkets.com/research/d6...llinresist
New Drug Applications, Quarterly Results, and University Partnerships - Analyst Notes on Celgene, HCA, Thermo Fisher Scientific, Cubist and Agilent
PR Newswire - Fri May 02, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Celgene Corporation (NASDAQ: CELG), HCA Holdings Inc. (NYSE: HCA), Thermo Fisher Scientific Inc. (NYSE: TMO), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agilent Technologies Inc. (NYSE: A). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1941-100free.
Global Opioid-Induced Constipation (OIC) Clinical Trials Report 2014 - Analysis of Top 19 Companies/Organisations
M2 - Mon Apr 28, 5:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4gnshl/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014" report to their offering. Opioid-Induced Constipation (OIC) Global Clinical Trials Review, H1, 2014" provides data on the Opioid-Induced Constipation (OIC) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid-Induced Constipation (OIC). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid-Induced Constipation (OIC). Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Organisations - Salix Pharmaceuticals Ltd. - AstraZeneca PLC - Mundipharma International Limited - Shionogi & Co., Ltd. - Cubist Pharmaceuticals, Inc. - Theravance, Inc. - Pfizer Inc. - Novartis AG - Alkermes Plc - Alkermes Inc. (Inactive) - Friedrich-Schiller-Universitat Jena - The University of Vermont - St. John's Health System - VU University Medical Center - Shriners Hospitals for Children - Kuopio University Hospital - British Columbia Cancer Agency - UMC Utrecht Holding BV - Ullevaal University Hospital For more information visit http://www.researchandmarkets.com/research/4g...oidinduced
Global Opioid Induced Bowel Dysfunction Clinical Trials Review 2014 Featuring the Top 9 Companies/Institutes in the Field
M2 - Mon Apr 28, 5:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qxs8hs/opioid_induced) has announced the addition of the "Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014" report to their offering. Opioid Induced Bowel Dysfunction Global Clinical Trials Review, H1, 2014" provides data on the Opioid Induced Bowel Dysfunction clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Opioid Induced Bowel Dysfunction. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Opioid Induced Bowel Dysfunction. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Clinical Trial Overview of Top Companies & Institutes - GlaxoSmithKline plc - Cubist Pharmaceuticals, Inc. - Salix Pharmaceuticals Ltd. - Sucampo Pharmaceuticals, Inc. - Shionogi & Co., Ltd. - Helsinn Holding S.A. - Yokohama City University Hospital - Mech-Sense - Kuopio University Hospital For more information visit http://www.researchandmarkets.com/research/qx...id_induced
Global Urinary Tract Infections Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 4:03AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dq83tc/urinary_tract) has announced the addition of the "Global Urinary Tract Infections Therapeutic Pipeline Review 2014" report to their offering. hensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Nippon Shinyaku Co., Ltd. - Paratek Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - CytoTools AG - Achaogen Inc. - MerLion Pharmaceuticals Pte Ltd - Osel Inc. - FOB Synthesis, Inc. - Sequoia Sciences, Inc. - Tetraphase Pharmaceuticals Inc. - Da Volterra - Biota Pharmaceuticals, Inc. - Adenium Biotech ApS Drug Profiles - prulifloxacin - (ceftolozane tazobactam) - eravacycline - (ceftazidime avibactam) - dexamethasone acetate - plazomicin - delafloxacin - LACTIN-V - (ceftaroline avibactam) - UtiSept - finafloxacin - MK-7655 - omadacycline tosylate - S-649266 - Vaccine Program - NXB-4221 - MAR Program - GP-4 - Micselon - cefepime - Nu-3 - DAV-210 - GyrB/ParE Antibiotic - AA-139 - FSI-1686 - NXC-4720 For more information visit http://www.researchandmarkets.com/research/dq...nary_tract
Global Opioid-Induced Constipation (OIC) Therapeutics Pipeline Review 2014 - Analysis of 11 Companes & 13 Drug Profiles
M2 - Wed Apr 23, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l3fs6f/opioidinduced) has announced the addition of the "Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - AstraZeneca PLC - Cubist Pharmaceuticals, Inc. - Progenics Pharmaceuticals, Inc. - Cosmo Pharmaceuticals S.p.A - Theravance, Inc. - Sucampo Pharmaceuticals, Inc. - AIKO Biotechnology, Inc. - Synergy Pharmaceuticals, Inc. - S.L.A. Pharma AG - Develco Pharma Schweiz AG Drug Profiles - naloxegol - lubiprostone - methylnaltrexone bromide - methylnaltrexone bromide - naldemedine - bevenopran - naloxone hydrochloride PR - methylnaltrexone bromide - TD-1211 - naloxone hydrochloride SR - SP-333 - naloxone hydrochloride - (6-beta-naltrexol oxycodone) For more information visit http://www.researchandmarkets.com/research/l3...oidinduced
Cubist Pharmaceuticals Reports First Quarter 2014 Financial Results
Business Wire - Tue Apr 22, 3:00PM CDT
--Non-GAAP Adjusted Operating Income of $18.8 Million; GAAP Operating Income of $28.3 Million
Cubist Pharmaceuticals Issues Voluntary Nationwide Recall of One Lot of CUBICIN (daptomycin for injection) 500 mg in 10 mL single use vials Due to Presence of Particulate Matter
Business Wire - Fri Apr 18, 10:59AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced it is voluntarily recalling one lot of CUBICIN(R) (daptomycin for injection) to the user level due to the presence of particulate matter, reported via customer complaint and identified as glass particles, found in a single vial from this lot, produced by a contract manufacturer.
Global Klebsiella Pneumoniae Infections Pipeline Review 2014 - Analysis of 12 Companies & 21 Drug Profiles
M2 - Thu Apr 17, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frwd77/klebsiella) has announced the addition of the "Klebsiella Pneumoniae Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Klebsiella Pneumoniae Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Klebsiella Pneumoniae Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Klebsiella Pneumoniae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Klebsiella Pneumoniae Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Klebsiella Pneumoniae Infections - Companies Involved in Therapeutics Development - Dainippon Sumitomo Pharma Co., Ltd. - Melinta Therapeutics, Inc - Cubist Pharmaceuticals, Inc. - Pfizer Inc. - Soligenix, Inc. - FOB Synthesis, Inc. - Phico Therapeutics Ltd. - Trana Discovery, Inc. - Cantab Biopharmaceuticals Limited - Procarta Biosystems Ltd - Northern Antibiotics Oy - Arsanis Biosciences GmbH Drug Profiles - CB-618 - RX-04 - Drugs for Gram-Negative Nonsocomial Infections - CB-027 - SM-295291 - SM-369926 - SGX-942 - Small Moleule To Inhibit Lipopolysaccharide For Nosocomial Infections - Antimicrobial Compounds for Bacterial Infections - NAB-741 - NAB-7061 - Monoclonal Antibody For Klebsiella Pneumoniae Infections - IBN-1 - PMBN-fMLF - PMEN-fMLF - FSI-1686 - SASPject PT-3.X - RX-05 - Snare Antibacterial For Gram Negative Infections - Antibiotics For Hospital-Acquired Gram-Negative Bacterial Infections - MVX-506 For more information visit http://www.researchandmarkets.com/research/frwd77/klebsiella
Cubist to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Business Wire - Tue Apr 15, 7:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its first quarter financial results, business activities, and financial outlook.
Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol. Zacks Industry Outlook Highlights: Eli Lilly, AstraZeneca, Shire, Salix and Cubist Pharmaceuticals
PR Newswire - Thu Mar 27, 8:30AM CDT
Today, Zacks Equity Research discusses the Pharma & Biotech, including Eli Lilly (NYSE:LLY-Free Report), AstraZeneca (NYSE:AZN-Free Report), Shire (Nasdaq:SHPG-Free Report), Salix (Nasdaq:SLXP-Free Report) and Cubist Pharmaceuticals (Nasdaq:CBST-Free Report).
Avanir Pharmaceuticals names Dr Mark Corrigan to board
M2 - Thu Mar 20, 5:02AM CDT
Biopharmaceutical company Avanir Pharmaceuticals (NasdaqGS:AVNR) revealed on Wednesday the addition of Dr Mark Corrigan to its board of directors.
Cellceutix Enrolls First Patients in Phase 2b ABSSSI Clinical Trial
Marketwire - Wed Feb 26, 5:00AM CST
Cellceutix Corporation (OTCQB: CTIX) (the "Company"
, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the first patients have been enrolled and treated in the Company's Phase 2b clinical trial of Brilacidin in patients with Acute Bacterial Skin and Skin Structure Infection (ABSSSI). Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics
M2 - Tue Feb 18, 2:37AM CST
Research and Markets (http://www.researchandmarkets.com/research/kkvg3x/competitor) has announced the addition of the "Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics" report to their offering. Clostridium difficile infections (CDI) are a major public health concern. CDI are becoming increasingly prevalent in hospitals, long-term and primary-care facilities, primarily in patients whose normal intestinal flora have been compromised by antibiotic treatment. CDI primary virulence mechanismis the production of two toxins, TcdA and TcdB, which glucosylate Rho-family GTPases, disrupt the actin cytoskeleton, and causing cytotoxicity and inflammation. The present Competitive Intelligence Report about prophylaxis and therapy of Clostridium difficile infections provides a competitor evaluation in the field of new molecules or microorganisms for prevention or treatment of Clostridium difficle infections as of January 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of antibodies, proteins, peptides, vaccines, microorganisms and small molecules for prevention and treatment of Clostridium difficile infections. In addition, the report lists company-specific R&D pipelines of C. difficile vaccines and therapeutics. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. Key Topics Covered - C. difficile Vaccines - C. difficile Antibodies - C. difficile Antibiotics - C. difficile targeting Microorganisms - C. difficile Anti-Infectives - Corporate C. difficile Vaccines & Therapeutics R&D Pipelines Companies Mentioned - Actelion - AIMM Therapeutics - AmpliPhi Biosciences - Astellas Pharma - AstraZeneca (MedImmune) - Aviex Technologies - Biota Pharmaceuticals - Crestone - Cubist Pharmaceuticals - DaVolterra - Immuron - Merck - Novacta Therapeutics - Novartis - Pfizer - Prokarium - Rebiotix - Sanofi Pasteur - Seres Health - Shire (ViroPharma) - Stellar Biotechnologies - Summit - Synthetic Biologics - Valneva - VaxInnate - Venenum Biodesign For more information visit http://www.researchandmarkets.com/research/kkvg3x/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013 Report
M2 - Thu Feb 06, 2:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/c57d4f/clostridium) has announced the addition of the "Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013" report to their offering. 'Clostridium Difficile Infections (Clostridium Difficile Associated Disease) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). Scope - A snapshot of the global therapeutic scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). - A review of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Unknown Stage Products Assessment by Monotherapy Products Assessment by Combination Products Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Assessment by Therapeutic Class Drug Profiles Featured News & Press Releases Companies Mentioned Sequella, Inc. MedImmune, LLC Daiichi Sankyo Company, Limited AmpliPhi Biosciences Corporation Merck & Co., Inc. Novartis AG Cubist Pharmaceuticals, Inc. The Medicines Company Pfizer Inc. Ranbaxy Laboratories Limited ViroPharma Incorporated Paratek Pharmaceuticals, Inc. Oragenics, Inc. Immuron Limited Summit Corporation plc Novabiotics Ltd ImmunoBiology Ltd. Aquapharm Biodiscovery Limited Microbiotix, Inc. Synthetic Biologics, Inc. AIMM Therapeutics B.V. and many more.... For more information visit http://www.researchandmarkets.com/research/c5...lostridium About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Catabasis Announces Appointment of Kenneth M. Bate as Independent Director
PR Newswire - Tue Feb 04, 7:00AM CST
Catabasis Pharmaceuticals Inc. today announced the appointment of Kenneth M. Bate to its board of directors as an independent director. Mr. Bate is an experienced biotechnology executive having led companies at various stages of development. He currently is chairman of the board of Cubist Pharmaceuticals, Inc., and is a director of BioMarin Pharmaceuticals, AVEO Pharmaceuticals and TransMedics, Inc. Mr. Bate currently serves as an independent biotechnology industry consultant and previously has served as president and chief executive officer of Archemix Corp. and NitroMed Inc., chief financial officer of Millennium Pharmaceuticals Inc. and Biogen Inc., and co-founded JSB Partners LLC, a banking and advisory services firm for biopharmaceutical and life sciences companies. He holds an MBA from the Wharton School of the University of Pennsylvania and a BA from Williams College.
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 03, 2:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/fg3mhf/hospital_acquired) has announced the addition of the "Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013" report to their offering. 'Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP). Scope - A snapshot of the global therapeutic scenario for Hospital Acquired Pneumonia (HAP). - A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned AstraZeneca PLC Cubist Pharmaceuticals, Inc. Basilea Pharmaceutica AG Aridis Pharmaceuticals LLC Tetraphase Pharmaceuticals Inc. Meiji Seika Pharma Co., Ltd. Biota Pharmaceuticals, Inc. Adenium Biotech ApS Melinta Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/fg...l_acquired About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Bacteremia - Pipeline Review, H2 2013 Report
M2 - Mon Jan 27, 2:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/qv84kq/bacteremia) has announced the addition of the "Bacteremia - Pipeline Review, H2 2013" report to their offering. 'Bacteremia - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bacteremia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bacteremia. Scope - A snapshot of the global therapeutic scenario for Bacteremia. - A review of the Bacteremia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bacteremia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Bacteremia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Bacteremia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned Cubist Pharmaceuticals, Inc. Nabriva Therapeutics AG Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/qv84kq/bacteremia About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
